Clinical Trial Detail

NCT ID NCT00975767
Title A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MethylGene Inc.
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Glesatinib

Erlotinib + Glesatinib

Age Groups: adult

No variant requirements are available.